PIK3CA mutations appear to be the most common driver mutations in breast cancer, with H1047R and E545K being the most common, accounting for approximately 60% of all PIK3CA mutations, with good therapeutic implications. Given the low sensitivity and high cost of current genotyping methods, we offer a fast, simple and inexpensive assay for PIK3CA H1047R and E545K mutation screening in clinical materials.